Summit Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Summit Therapeutics has a total shareholder equity of $437.9M and total debt of $24.5M, which brings its debt-to-equity ratio to 5.6%. Its total assets and total liabilities are $502.9M and $64.9M respectively.
Key information
5.6%
Debt to equity ratio
US$24.50m
Debt
| Interest coverage ratio | n/a |
| Cash | US$486.90m |
| Equity | US$437.92m |
| Total liabilities | US$64.93m |
| Total assets | US$502.85m |
Recent financial health updates
Recent updates
The Play On Summit Therapeutics
Jan 05Summit Therapeutics Stock Set To Soar By Mid-2025 On HARMONi Phase 3 Trial
Dec 02Summit Therapeutics (NASDAQ:SMMT) Has Debt But No Earnings; Should You Worry?
Nov 08
Summit Therapeutics: Cancer Drug With Great Potential On 'Fast Track' To US Market
Oct 04Summit Therapeutics Bests Merck's Top Selling Drug In Phase III Trial
Sep 19Summit Therapeutics: World Lung Data Not Enough For Ivonescimab To Unseat Keytruda (Yet)
Sep 09Summit Therapeutics May Have Further Upside From Here
Aug 03Summit Therapeutics Stock: Plunging Despite A Win?
May 31Summit Therapeutics' Ivonescimab: Strong Buy Its Dual-Action Approach To Cancer
May 06Summit Therapeutics: A Strategic Analysis Of Ivonescimab's Progress
Jan 30Summit Therapeutics slips on plans to terminate study for lead candidate
Oct 04Summit Therapeutics: Developing Antibiotics Is A Noble Cause But The Company Is Wise To Expand Its Portfolio
Aug 17Summit Therapeutics GAAP EPS of -$0.17, revenue of $0.23M
Aug 11Summit to explore additional trial for its bacteria-induced colon infection drug
Jul 14Summit Therapeutics - Disappointing Data But Not An Outright Failure
Dec 23Summit Therapeutics: A Full Investment Analysis Of This Antibiotic Innovator
Jun 22Summit Therapeutics to join Russell 3000 Index
Jun 08Financial Position Analysis
Short Term Liabilities: SMMT's short term assets ($490.3M) exceed its short term liabilities ($59.0M).
Long Term Liabilities: SMMT's short term assets ($490.3M) exceed its long term liabilities ($5.9M).
Debt to Equity History and Analysis
Debt Level: SMMT has more cash than its total debt.
Reducing Debt: SMMT's debt to equity ratio has increased from 0% to 5.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SMMT has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: SMMT has sufficient cash runway for 2.4 years if free cash flow continues to reduce at historical rates of 42.9% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 04:58 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Summit Therapeutics Inc. is covered by 17 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gary Waanders | Bryan Garnier & Co |
| Timothy Chiang | BTIG |
| Arlinda Lee | Canaccord Genuity |